Nurix Therapeutics clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093NX-5948, PirtobrutinibRecruiting2029-10Estimated

Phase 2 1 trial

Phase 1 / 2 1 trial

TrialDrugs studiedStatusPrimary completion
Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006NX-5948, obinutuzumab, rituximab, venetoclaxRecruiting2033-05Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

NCT07516093 · Nurix Therapeutics, Inc.

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC). After: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC.

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective response rate as determined by an Independent Review Committee (IRC). After: Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC).

Check registry source